GTX Corp Provides Corporate Update And Reports Second Quarter 2015 Financial Results

MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (Nasdaq: GTXI) today reported financial results for the quarter and six months ended June 30, 2015, and highlighted recent accomplishments and developments. The Company has initiated its Phase 2 clinical trial of enobosarm in androgen receptor positive (AR+) triple negative breast cancer (TNBC) and anticipates initiating this quarter an additional Phase 2 clinical study of enobosarm to treat AR+ and estrogen receptor positive (ER+) breast cancer.

Help employers find you! Check out all the jobs and post your resume.

Back to news